• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

PCSK9 and cancer: Rethinking the link
Biomed Pharmacother. 2021 May 28;140:111758. doi: 10.1016/j.biopha.2021.111758. Online ahead of print.ABSTRACTBACKGROUND: Cancer is emerging as a major problem globally, as it accounts for the second cause of death despite medical advances. According to epidemiological and basic studies, cholesterol is involved in cancer progression and there are abnormalities in cholesterol metabolism of cancer cells including prostate, breast, and colorectal carcinomas. However, the importance of cholesterol in carcinogenesis and thereby the role of cholesterol homeostasis as a therapeutic target is still a debated area in cancer therapy...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - May 31, 2021 Category: Drugs & Pharmacology Authors: Khadijeh Mahboobnia Matteo Pirro Ettore Marini Francesco Grignani Evgeny E Bezsonov Tannaz Jamialahmadi Amirhossein Sahebkar Source Type: research

The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy
This study was designed to check the combined effect of CD133 siRNA and Oxaliplatin on proliferation, migration, apoptosis, and stemness properties of CRC cells in the HT-29 cell line. MTT assay was performed to define the combined effect of CD133 siRNA and Oxaliplatin on the viability of HT-29 cells, and it showed that the combination of CD133 siRNA and Oxaliplatin could reduce the IC50 of this drug from 32.85 to 19.75 nmol. In order to figure out the effect of this combination therapy on CD133 expression at the gene and protein level, qRT-PCR and western blot were exploited, respectively. The results demonstrated that th...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 16, 2021 Category: Drugs & Pharmacology Authors: Zahra Asadzadeh Behzad Mansoori Ali Mohammadi Tohid Kazemi Ahad Mokhtarzadeh Dariush Shanehbandi Nima Hemmat Afshin Derakhshani Oronzo Brunetti Sahar Safaei Marjan Aghajani Souzan Najafi Nicola Silvestris Behzad Baradaran Source Type: research

The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy.
This study was designed to check the combined effect of CD133 siRNA and Oxaliplatin on proliferation, migration, apoptosis, and stemness properties of CRC cells in the HT-29 cell line. MTT assay was performed to define the combined effect of CD133 siRNA and Oxaliplatin on the viability of HT-29 cells, and it showed that the combination of CD133 siRNA and Oxaliplatin could reduce the IC50 of this drug from 32.85 to 19.75 nmol. In order to figure out the effect of this combination therapy on CD133 expression at the gene and protein level, qRT-PCR and western blot were exploited, respectively. The results demonstrated that th...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 13, 2021 Category: Drugs & Pharmacology Authors: Asadzadeh Z, Mansoori B, Mohammadi A, Kazemi T, Mokhtarzadeh A, Shanehbandi D, Hemmat N, Derakhshani A, Brunetti O, Safaei S, Aghajani M, Najafi S, Silvestris N, Baradaran B Tags: Biomed Pharmacother Source Type: research

Long noncoding RNA CASC21 exerts an oncogenic role in colorectal cancer through regulating miR-7-5p/YAP1 axis.
CONCLUSION: Collectively, these results suggest that CASC21 functions as a ceRNA that plays an oncogenic role in the progression of colorectal cancer by regulating the miR-7-5p/YAP1 axis. LncRNA CASC21 might be a potential target for therapy of colorectal cancer. PMID: 31731190 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 10, 2019 Category: Drugs & Pharmacology Authors: Zheng Y, Nie P, Xu S Tags: Biomed Pharmacother Source Type: research

GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer.
CONCLUSION: This study identifies the gene GDPD5 as an effector of chemoresistance and metastasis in CRC. Furthermore, our results demonstrate that miR-195-5p is a potent suppressor of GDPD5 and that, as such, it significantly increases chemosensitivity and apoptosis in chemoresistant CRC cells. This study thus not only identifies potential prognostic biomarkers of CRC, but it also opens the possibility for incorporating miR-195-5p into current therapeutic regimens to overcome barriers to successful CRC treatment. PMID: 29635904 [PubMed - in process]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 14, 2018 Category: Drugs & Pharmacology Authors: Feng C, Zhang L, Sun Y, Li X, Zhan L, Lou Y, Wang Y, Liu L, Zhang Y Tags: Biomed Pharmacother Source Type: research

Suppression of Capn4 by microRNA-1271 impedes the proliferation and invasion of colorectal cancer cells.
In this study, we aimed to investigate the potential role of Capn4 in CRC and the regulation of Capn4 by microRNAs (miRNAs). Here, we found that Capn4 expression was highly up-regulated in CRC cell lines. Knockdown of Capn4 by siRNA significantly inhibited the proliferation and invasion of CRC cell lines. Furthermore, knockdown of Capn4 suppressed Wnt signaling in CRC cells. Interestingly, Capn4 was found to be a target gene of miR-1271, a tumor suppressive miRNA. The results showed that miR-1271 negatively regulated Capn4 expression in CRC cells. An inverse correlation between miR-1271 and Capn4 was also shown in CRC clin...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - January 10, 2018 Category: Drugs & Pharmacology Authors: Li J, Xu J, Yan X, Jin K, Li W, Zhang R Tags: Biomed Pharmacother Source Type: research

FAM83D knockdown regulates proliferation, migration and invasion of colorectal cancer through inhibiting FBXW7/Notch-1 signalling pathway.
In conclusion, FAM83D knockdown promoted colorectal cancer cell apoptosis, inhibited cell proliferation, cell migration and invasion, which might be associated with inhibiting the FBXW7/Notch1 signal pathway. Our findings indicated that FAM83D is a promising molecular target for colorectal cancer treatment. PMID: 28407575 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 10, 2017 Category: Drugs & Pharmacology Authors: Mu Y, Zou H, Chen B, Fan Y, Luo S Tags: Biomed Pharmacother Source Type: research

Circular BANP, an upregulated circular RNA that modulates cell proliferation in colorectal cancer.
Abstract Circular RNAs (circRNAs) are recently identified as widespread and diverse endogenous noncoding RNAs that may harbor vital functions in human and animals. However, the role of circRNAs in the process of tumorigenesis and development of colorectal cancer (CRC) remains vague. Here we characterized the circRNA expression profile from three paired CRC cancerous and adjacent normal tissues by human circRNA array, and identified 136 significantly overexpressed circRNAs and 243 downregulated circRNAs in CRC cancerous tissues (>2-fold changes). We further validated one circRNA generated from Exon 5-11 of BANP ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - January 15, 2017 Category: Drugs & Pharmacology Authors: Zhu M, Xu Y, Chen Y, Yan F Tags: Biomed Pharmacother Source Type: research

The role of microRNAs in colorectal cancer.
Abstract Colorectal cancer (CRC) is still the third most common cancer in the world. Mechanism of CRC tumorigenesis has been widely studied at the molecular levels, and has been recently entered the area of microRNAs. MicroRNAs are small 19 to 22 nucleotides of RNA that engage in the regulation of cell differentiation, apoptosis, and cell cycle progression. MicroRNAs are similar to small interfering RNA (siRNA), that post-transcriptionally regulate gene expression and control various cellular mechanisms. They are important factors in the carcinogenesis of CRC, one of the most important factors includes microRNA. M...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 30, 2016 Category: Drugs & Pharmacology Authors: Mohammadi A, Mansoori B, Baradaran B Tags: Biomed Pharmacother Source Type: research

BACH1 silencing by siRNA inhibits migration of HT-29 colon cancer cells through reduction of metastasis-related genes.
CONCLUSION: Our results indicated that BACH1 down-regulation in HT29 CRC cells had no effect on cell growth but did inhibit cell migration by decreasing metastasis-related genes expression. Collectively, these results suggest that BACH1 may function as an oncogenic driver in colon cancer and may represent as a potential target of gene therapy for CRC treatment. PMID: 27657827 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 18, 2016 Category: Drugs & Pharmacology Authors: Davudian S, Shajari N, Kazemi T, Mansoori B, Salehi S, Mohammadi A, Shanehbandi D, Shahgoli VK, Asadi M, Baradaran B Tags: Biomed Pharmacother Source Type: research

miR-892a regulated PPP2R2A expression and promoted cell proliferation of human colorectal cancer cells.
Abstract Colorectal cancer (CRC) is one of the most common malignancy cancers in the world. Aberrant microRNA expression is involved in human diseases including cancer. In the present study, we investigated the miR-892a's role in CRC cell proliferation. We found that miR-892a was frequently upregulated in human colorectal cancer tissues and cell lines compared with the matched tumor adjacent tissues and normal colonic cell line FHC. Overexpression of miR-892a promoted cell proliferation and colony formation of CRC. Bioinformatics analysis further revealed PPP2R2A was identified as a potential miR-892a. Overexpress...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - May 1, 2015 Category: Drugs & Pharmacology Authors: Liang WL, Cao J, Xu B, Yang P, Shen F, Sun Z, Li WL, Wang Q, Liu F Tags: Biomed Pharmacother Source Type: research